GO:0043687 post-translational protein modification: Regulatory Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043687 (post-translational protein modification) describes the covalent alteration of amino acids in a protein after it has been fully translated and released from the ribosome.
• PTMs include phosphorylation, ubiquitination, acetylation, glycosylation, methylation, SUMOylation, and many others that expand proteome diversity far beyond the ~20,000 human genes.
• PTMs regulate protein stability, localization, activity, and interactions, and are central to nearly every signaling pathway and cellular process.
• Dysregulated PTMs are linked to cancer, neurodegeneration, immune disorders, and infectious disease, making PTM enzymes attractive therapeutic targets.
• Chemical proteomics and mass spectrometry are the primary tools for discovering and quantifying PTMs at scale.
• CRISPR-based knockout, knock-in, and point-mutation models enable causal testing of specific PTM sites and writer/eraser enzymes.
Description
Post-translational protein modification (PTM), annotated as GO:0043687, is the biological process by which one or more amino acids in a protein are covalently altered after the protein has been completely translated and released from the ribosome. This definition encompasses a vast array of chemical modifications, including phosphorylation, ubiquitination, acetylation, glycosylation, methylation, SUMOylation, and proteolytic cleavage, each catalyzed by dedicated enzymes and often reversed by opposing enzymes. Because PTMs can change a protein's stability, enzymatic activity, subcellular localization, and interaction partners, they dramatically expand the functional repertoire of the proteome beyond what is encoded by the genome. For researchers, GO:0043687 is a central node connecting cell signaling, gene regulation, and disease. Mass-spectrometry-based proteomics has revealed that a large fraction of the human proteome carries at least one PTM, and crosstalk between different modifications can create complex regulatory codes. PTM enzymes are frequently mutated or dysregulated in cancer, neurodegeneration, and immune disorders, and they are being actively pursued as drug targets. Understanding which PTMs occur on which proteins, how they are written and erased, and what phenotypic consequences they produce is therefore a major goal of modern biomedical research. This article provides a research-grade overview of GO:0043687, covering its definition, biological importance, core mechanisms, key genes, regulation, disease links, experimental models, and methods. It is intended for scientists who need a concise, citation-backed reference for grant writing, experimental design, and AI-assisted literature retrieval.
post-translational protein modification At A Glance
| GO ID | GO:0043687 |
|---|---|
| GO term | post-translational protein modification |
| Ontology | biological_process |
| Synonym | post-translational modification; posttranslational modification; PTM; post-translational amino acid modification |
| Definition | The process of covalently altering one or more amino acids in a protein after the protein has been completely translated and released from the ribosome. |
| Major function | Covalently modifies proteins to regulate their activity, stability, localization, and interactions, thereby expanding proteome diversity. |
| Example modifications | Phosphorylation, ubiquitination, acetylation, glycosylation, methylation, SUMOylation, proteolytic cleavage. |
| Key enzyme classes | Kinases, phosphatases, ubiquitin ligases, deubiquitinases, acetyltransferases, deacetylases, glycosyltransferases, methyltransferases. |
| Research relevance | Central to cell signaling, disease mechanisms, drug target discovery, and biomarker development. |
What Is GO:0043687?
In simple terms, post-translational protein modification (GO:0043687) is what happens to a protein after it has been built. The ribosome first synthesizes a polypeptide chain; once that chain is complete and released, enzymes can attach chemical groups (such as phosphate, acetyl, methyl, ubiquitin, or sugar chains) to specific amino acids, or cleave the chain. These covalent changes are not encoded directly in the DNA sequence but are essential for the protein to function correctly.
Why Is post-translational protein modification Important in Cell Biology?
GO:0043687 is important because it is one of the main mechanisms by which cells convert a static genome into a dynamic, responsive proteome. Nearly every signaling pathway depends on reversible PTMs such as phosphorylation and ubiquitination, and PTM crosstalk can integrate multiple inputs into a single biological decision. Because PTM enzymes are often druggable and disease-associated, they represent a rich source of therapeutic targets and biomarkers.
• PTMs regulate protein stability, activity, localization, and protein-protein interactions, making them central to signal transduction.
• PTM crosstalk and combinatorial modification create a complex regulatory code that expands proteome diversity.
• Dysregulated PTMs contribute to cancer, neurodegeneration, immune disorders, and infectious disease.
• PTM enzymes such as kinases and ubiquitin ligases are major drug target classes.
• Chemical proteomics enables global mapping of PTMs and their dynamic changes.
• PTMs influence phase separation and biomolecular condensate formation, linking modification state to cellular organization.
• PTMs are key regulators of ciliary protein trafficking and other specialized transport processes.
• PTM profiles can serve as biomarkers for disease diagnosis and prognosis.
• Bacterial pathogens use PTM-like toxin modification to control virulence, highlighting broad biological relevance.
• CRISPR-based models allow causal testing of specific PTM sites and enzymes in disease phenotypes.
What Happens During post-translational protein modification?
Substrate recognition and writer enzyme recruitment
In simple terms: First, a modifying enzyme finds the right protein and the right spot on it.
PTM writer enzymes, such as kinases, acetyltransferases, and ubiquitin ligases, recognize specific sequence motifs or structural features in substrate proteins. This recognition is often regulated by prior modifications, adaptor proteins, or scaffolding interactions, ensuring that modifications occur at the correct time and place. For example, phosphorylation of a substrate can create a docking site for a ubiquitin ligase, illustrating how PTMs can be sequentially coupled.
Covalent attachment of the modifying group
In simple terms: The enzyme then chemically attaches a small group or protein tag to the target amino acid.
The actual modification step involves the formation of a covalent bond between the modifying group and a specific amino acid side chain. Common examples include the transfer of a phosphate group from ATP to serine, threonine, or tyrosine residues by kinases; the attachment of acetyl groups to lysine residues; and the conjugation of ubiquitin or ubiquitin-like proteins to lysines. These reactions are highly specific and are controlled by the catalytic activity of the writer enzyme and the availability of cofactors such as ATP, acetyl-CoA, or ubiquitin.
Reversal and editing by eraser enzymes
In simple terms: Other enzymes can remove the modification, making the process reversible.
Many PTMs are reversible. Phosphatases remove phosphate groups, deubiquitinases cleave ubiquitin chains, and deacetylases remove acetyl groups. This dynamic balance between writers and erasers allows cells to rapidly respond to changing conditions and is essential for proper signaling. The interplay between opposing enzymes determines the steady-state level of a given modification and its biological output.
Reader-mediated downstream effects
In simple terms: Special proteins read the modification and carry out its effects.
Once a PTM is deposited, it can be recognized by reader domains, such as SH2 domains for phosphotyrosine, bromodomains for acetyl-lysine, and ubiquitin-binding domains for ubiquitinated proteins. These readers translate the modification into downstream outcomes, including changes in protein-protein interactions, enzymatic activity, localization, or degradation. This writer-reader-eraser framework is a central concept in PTM biology.
Crosstalk and combinatorial modification
In simple terms: Different modifications can influence each other, creating a complex code.
PTMs do not occur in isolation. Phosphorylation can regulate subsequent ubiquitination, acetylation can block ubiquitination on the same lysine, and SUMOylation can compete with ubiquitination. This crosstalk enables combinatorial regulation and fine-tuning of protein function. Mass spectrometry-based studies have revealed extensive co-occurrence of modifications on the same proteins, highlighting the importance of integrative analysis.
Impact on phase separation and cellular organization
In simple terms: Modifications can change how proteins cluster together inside cells.
Recent evidence indicates that PTMs can regulate liquid-liquid phase separation, influencing the formation and properties of biomolecular condensates. For example, phosphorylation can alter the valency and charge of proteins, thereby promoting or inhibiting condensate formation. This links GO:0043687 to cellular organization, signaling, and disease mechanisms such as neurodegeneration.
Key Genes Involved in GO:0043687 post-translational protein modification
The following genes and protein families represent major writers, erasers, and readers of post-translational modifications, and they are widely studied in the context of GO:0043687.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PRKACA | Catalytic subunit of protein kinase A; phosphorylates serine/threonine residues | Model for kinase-substrate specificity and signaling |
| AKT1 | Serine/threonine kinase; phosphorylates many targets in growth and survival pathways | Cancer, metabolism, drug target |
| TP53 | Tumor suppressor regulated by phosphorylation, acetylation, and ubiquitination | Cancer biology, PTM crosstalk |
| MDM2 | E3 ubiquitin ligase that ubiquitinates TP53 | Cancer, protein degradation |
| UBB | Ubiquitin precursor; provides ubiquitin for conjugation | Ubiquitin system, proteostasis |
| UBC | Ubiquitin-conjugating enzyme; involved in ubiquitin chain formation | Ubiquitin signaling |
| SUMO1 | Small ubiquitin-like modifier; conjugated to lysines | SUMOylation, stress response |
| HDAC1 | Histone deacetylase; removes acetyl groups from histones and non-histone proteins | Epigenetics, transcription |
| EP300 | Histone acetyltransferase; acetylates histones and transcription factors | Transcription, cancer |
| OGT | O-GlcNAc transferase; adds O-GlcNAc to serine/threonine residues | Metabolism, signaling |
| BTRC | F-box protein; substrate receptor for SCF ubiquitin ligase complex | Ubiquitin-proteasome system |
| CUL1 | Scaffold protein of SCF ubiquitin ligase complexes | Ubiquitin ligase assembly |
| RNF2 | E3 ubiquitin ligase; component of Polycomb repressive complex 1 | Epigenetics, development |
| ATM | Kinase that phosphorylates DNA damage response proteins | DNA repair, cancer |
| CHEK2 | Kinase activated by ATM; phosphorylates cell cycle regulators | DNA damage checkpoint |
| MAPK1 | Mitogen-activated protein kinase; phosphorylates transcription factors and other targets | Signaling, cancer |
| GSK3B | Serine/threonine kinase; phosphorylates many substrates including glycogen synthase | Metabolism, neurodegeneration |
| PIN1 | Peptidyl-prolyl isomerase; recognizes phosphorylated Ser/Thr-Pro motifs | Signaling, cancer, neurodegeneration |
How Is post-translational protein modification Regulated?
PTM processes are regulated at multiple levels. Writer and eraser enzymes are themselves subject to transcriptional control, post-translational modification, and spatial compartmentalization. Signaling pathways such as mTOR, DNA damage response, and stress-activated MAPK cascades modulate the activity of many PTM enzymes, thereby coordinating modifications with cellular state. Additionally, the availability of cofactors and substrates, as well as the presence of scaffolding proteins, can influence which proteins are modified and when. Crosstalk between modifications provides another layer of regulation, as one PTM can create or destroy a recognition site for another enzyme.
post-translational protein modification and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TP53 | Cancer; impaired tumor suppression due to altered PTMs | Knock-in of phosphorylation-site mutations; KO of MDM2 |
| MDM2 | Cancer; overexpression leads to TP53 degradation | Overexpression; point mutation of ubiquitin ligase domain |
| LRRK2 | Parkinson's disease; kinase hyperactivity and phosphorylation | Knock-in of G2019S mutation; KO |
| MAPT | Tauopathies; hyperphosphorylation and aggregation | Knock-in of phosphorylation-site mutations; overexpression |
| SUMO1 | Neurodegeneration; altered SUMOylation | KO; knock-in of conjugation-deficient mutant |
Cancer
Dysregulated PTMs are a hallmark of cancer. Mutations in kinases, ubiquitin ligases, and deubiquitinases can lead to aberrant activation of oncogenic pathways or stabilization of oncoproteins. For example, altered phosphorylation of TP53 or its regulators can impair tumor suppression, and ubiquitin-mediated degradation of tumor suppressors is frequently disrupted in tumors. PTM enzymes are therefore major targets for cancer therapy, and PTM-based biomarkers are being developed for diagnosis and prognosis.
Neurodegeneration
Protein aggregation and impaired proteostasis are common features of neurodegenerative diseases. Aberrant phosphorylation, ubiquitination, and SUMOylation contribute to the accumulation of misfolded proteins such as tau and alpha-synuclein. PTM crosstalk and phase separation are increasingly recognized as mechanisms that drive pathological aggregate formation. Targeting PTM enzymes or reader proteins is being explored as a therapeutic strategy.
Infectious disease
Pathogens exploit PTM systems to control virulence. For example, lactate-mediated post-translational toxin modification regulates Staphylococcus aureus virulence, demonstrating that PTM-like mechanisms can directly influence bacterial pathogenesis. Understanding these modifications may lead to new anti-virulence strategies.
Immune disorders and immunotherapy
PTMs play critical roles in immune signaling and antigen presentation. Advances in PTM research have revealed that modifications on immune checkpoint proteins and cytokines can modulate immune responses, and PTM-based strategies are being explored to enhance cancer immunotherapy. Dysregulated PTMs can also contribute to autoimmune and inflammatory diseases.
From post-translational protein modification-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a specific PTM site on a protein regulate its stability? | Point mutation (e.g., Ser to Ala) via CRISPR knock-in |
| Is a writer enzyme required for a phenotype? | CRISPR knockout of the enzyme gene |
| Does a disease-associated mutation alter PTM recognition? | Knock-in of the patient mutation |
| Where and when is a modified protein expressed? | Tagged knock-in (e.g., HA, GFP) for imaging |
| Does overexpression of a PTM enzyme drive transformation? | Overexpression via CRISPR activation or lentiviral delivery |
| Which PTM readers bind a modified protein? | Knock-in of tagged reader domains; proteomics |
How to Study the post-translational protein modification Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | Mass and sequence of modified peptides | Global PTM mapping and quantification |
| Phosphoproteomics | Phosphorylation sites and levels | Signaling pathway analysis |
| Ubiquitinomics | Ubiquitinated proteins and chain types | Proteostasis and degradation studies |
| Chemical proteomics | Activity and targets of PTM enzymes | Drug target engagement and selectivity |
| Modification-specific antibodies | Presence and localization of specific PTMs | Western blot, IF, IP |
| CRISPR knockout screens | Gene requirement for PTM-dependent phenotypes | Functional validation of PTM enzymes |
| Proximity labeling | Protein-protein interactions in PTM pathways | Mapping writer-reader networks |
Mass spectrometry-based proteomics
Mass spectrometry is the primary method for identifying and quantifying PTMs. Enrichment strategies using antibodies or chemical probes followed by LC-MS/MS allow global mapping of phosphorylation, ubiquitination, acetylation, and other modifications. Quantitative proteomics can compare PTM levels across conditions or disease states.
Chemical proteomics
Chemical proteomics uses activity-based probes and bioorthogonal chemistry to profile PTM enzymes and their substrates. This approach enables the discovery of new PTM regulators and the assessment of drug selectivity.
Antibody-based detection and imaging
Modification-specific antibodies are widely used in western blotting, immunoprecipitation, and immunofluorescence to detect and localize PTMs in cells and tissues. These methods provide spatial and temporal information that complements mass spectrometry.
CRISPR screening and functional genomics
Pooled CRISPR screens can systematically test the role of PTM enzymes and reader proteins in cellular phenotypes. Combined with PTM profiling, these screens can identify causal relationships between specific modifications and biological outcomes.
How CRISPR Can Be Used to Study GO:0043687 post-translational protein modification
Knockout
CRISPR knockout of a PTM writer, eraser, or reader gene eliminates its function, allowing researchers to test whether the modification is required for a given phenotype. For example, knocking out a kinase can reveal its role in cell proliferation or survival.
Point Mutation
CRISPR point mutation can change a specific amino acid in a substrate protein to prevent or mimic a modification (e.g., Ser to Ala to block phosphorylation, or Ser to Asp to mimic it). This approach provides causal evidence for the function of a single PTM site.
Knock-in
Knock-in of a tagged version of a protein (e.g., HA, GFP, or BirA tag) enables visualization, purification, and interactome analysis of the modified protein in its native context. Knock-in of disease-associated mutations can model their effects on PTM recognition.
Overexpression
Overexpression of a PTM enzyme or substrate can amplify the modification and its downstream effects, facilitating biochemical and phenotypic assays. CRISPR activation (CRISPRa) allows tunable overexpression without exogenous constructs.
How EDITGENE Supports post-translational protein modification Research
Researchers studying post-translational protein modification-related genes often need to determine whether a candidate gene is causally involved in a specific biological process or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such causal experiments, from knockout to precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for post-translational protein modification research.
Frequently Asked Questions About post-translational protein modification
What is post-translational protein modification (GO:0043687)?
It is the biological process of covalently altering one or more amino acids in a protein after it has been completely translated and released from the ribosome.
What are the main types of post-translational modifications?
Common types include phosphorylation, ubiquitination, acetylation, glycosylation, methylation, SUMOylation, and proteolytic cleavage.
What genes are involved in post-translational protein modification?
Genes encoding kinases, phosphatases, ubiquitin ligases, deubiquitinases, acetyltransferases, deacetylases, and other writer, eraser, and reader enzymes.
Why is post-translational modification important?
It regulates protein activity, stability, localization, and interactions, and is essential for nearly all cellular processes.
How are post-translational modifications studied?
Mass spectrometry-based proteomics, chemical proteomics, modification-specific antibodies, and CRISPR screens are commonly used.
What diseases are linked to abnormal post-translational modifications?
Cancer, neurodegeneration, immune disorders, and infectious diseases are among the major areas.
Can CRISPR be used to study post-translational modifications?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of specific PTM sites and enzymes.
What is the role of PTMs in cancer?
Dysregulated PTMs can activate oncogenic pathways or stabilize oncoproteins, and PTM enzymes are drug targets.
How do PTMs affect protein-protein interactions?
PTMs can create or destroy binding sites for reader domains, thereby modulating interaction networks.
What is PTM crosstalk?
It is the phenomenon where one modification influences the occurrence or function of another, creating a combinatorial code.
Conclusion
GO:0043687, post-translational protein modification, is a fundamental biological process that greatly expands the functional capacity of the proteome. Its dysregulation underlies numerous human diseases, and its enzymes are promising therapeutic targets. Advances in mass spectrometry, chemical proteomics, and CRISPR-based models continue to deepen our understanding of PTM biology and its translational potential.
References
- 1. Wang S et al.. 2022. Uncovering post-translational modification-associated protein-protein interactions.. Curr Opin Struct Biol 74:102352 PMID: 35334254
- 2. Zhang N et al.. 2024. Chemical proteomics approaches for protein post-translational modification studies.. Biochim Biophys Acta Proteins Proteom 1872(4):141017 PMID: 38641087
- 3. Tang M et al.. 2022. Avenues for post-translational protein modification prevention and therapy.. Mol Aspects Med 86:101083 PMID: 35227517
- 4. Wang Y et al.. 2024. Post-translational toxin modification by lactate controls Staphylococcus aureus virulence.. Nat Commun 15(1):9835 PMID: 39537625
- 5. Chaya T et al.. 2021. Post-translational modification enzymes as key regulators of ciliary protein trafficking.. J Biochem 169(6):633-642 PMID: 33681987
- 6. Salovska B et al.. 2023. Post-translational modification and phenotype.. Proteomics 23(3-4):e2200535 PMID: 36799530
- 7. Li Y et al.. 2023. Advances in post-translational modifications of proteins and cancer immunotherapy.. Front Immunol 14:1229397 PMID: 37675097
- 8. Liu Y et al.. 2024. Crosstalk between protein post-translational modifications and phase separation.. Cell Commun Signal 22(1):110 PMID: 38347544
